【MIT CEO x BioSpark】Boston线下活动｜biotech创业和startup公司管理

汇聚群英智慧，闪亮你我星光

Together, Spark Biomedicine!

BioSpark有幸请到了五位嘉宾(panelist), 从创始人(founder)、高管(executive)和投资人(investor)的角度，分享他们的故事和洞见。

这些嘉宾具有多样的职业背景和精彩的发展轨迹。在创业或加入startup前，有的嘉宾深耕于学术界，有的嘉宾负责世界一流药企和biotech的R&D部门，有的曾就职于管理咨询公司后转入药企管理层，有的则具有丰富的临床开发经验。

嘉宾们将分享他们在创业和管理startup的成功经验和心得体会。不论你是正在创业的，还是将要加入创业领域的，欢迎你带着你的经历、建议和疑问，与嘉宾和其他会员进行近距离接触。

通过这次分享，希望帮助大家破除一些迷思(myth), 了解biotech startup的生态环境，开拓视野和提高认知。

哪些会员能从此次分享活动获益？

- 未来有创业打算的(future founder/co-founders)

- 有兴趣加入startup工作的professional

- 有兴趣投资startup的投资人

活动组织：Jing Wang, Qinghong Yan, Hong Yue

Event Details

主题：Boston 线下活动——BioSpark 聊 biotech 创业和startup公司管理

时间：2023年6月9日周五 6:00PM EST

地点：MIT cambridge, MA, 活动提供晚餐

注册方式：点击“阅读原文”或扫描二维码注册

Speakers Intro

Jiang He, Ph.D.

Co-founder @ Vizgen

Jiang He is the scientific co-founder and head of Scientific Affairs in Vizgen, a life science company pioneering in single-cell spatial genomics. He completed his postdoc at MIT, Ph.D. at Harvard University in Xiaowei Zhuang’s lab, and B.S. from University of Science and Technology of China. His work focused on developing single molecule imaging techniques and applying them to study different biological processes. Within Vizgen, Jiang oversees the technology and application development, as well as the lab service division. Jiang has been recognized with numerous awards including Forbes 30 under 30 in Healthcare, Spotlight Scholar at AIF, and STAT Wunderkind awardee.

Tony W. Ho, M.D.

CSO & Senior Science Partner @ Pivotal Bioventure

Tony W. Ho, M.D., is Chief Scientific Officer and Senior Science Partner at Pivotal Bioventure. He was previously Executive Vice President and Head of R&D for CRISPR Therapeutics between 2017 and 2021, responsible for global R&D across all therapeutic areas of the company. During this period, Dr. Ho led and built a world-leading R&D platform with more than 10 product pipelines. Dr. Ho and his team have brought the first CRISPR-based therapy CTX001, three allogeneic CAR-T (CTX110 (CD19), 120 (BCMA), 130 (CD70)), and the first CRISPR edited pancreatic islet progenitor cells (VCTX210, VCTX211) from research bench to the clinic. Prior to CRISPR Therapeutics, Dr. Ho was SVP and Head of Oncology Integration and Innovation at AstraZeneca and oversaw the development and commercialization of Lynparza® (olaparib) and Imfinizi® (durvalumab). Before joining AstraZeneca, Dr. Ho was the head of Neurology and Ophthalmology at Merck, and before Merck, Dr. Ho was the Co-Founder and CSO of Neuronyx.

Dr. Ho received his M.D. from Johns Hopkins University and his B.S. in Electrical Engineering from UCLA. Dr. Ho has published more than 80 papers in a variety of fields and currently serves as an Adjunct Associate Professor of Neurology at the University of Pennsylvania and Assistant Professor of Neurology at Johns Hopkins University.

X. Shirley Liu, Ph.D.

Co-founder & CEO @ GV20 Therapeutics

Dr. X Shirley Liu is the co-founder and CEO of GV20 Therapeutics, a clinical stage immuno-oncology drug development company. GV20 utilizes CRISPR screens and AI approaches to identify novel cancer immunology drug targets, and uses a proprietary AI platform to de novo design fully-human functional antibodies with favorable developability profiles. GV20 is developing these antibodies into immuno-oncology drugs to be tested in the clinic.

Dr. Liu received PhD in Biomedical Informatics and PhD minor in Computer Science from Stanford University in 2002. Before joining GV20 in 2022, Dr. Liu has been a Professor of Biostatistics and Computational Biology at the Department of Data Science at Dana-Farber Cancer Institute (DFCI) and Harvard University. She was also the Director of the Center for Functional Cancer Epigenetics at the DFCI and an associate member of the Broad Institute of MIT and Harvard. Her research work focused on algorithm development and data integration modeling for translational cancer research. Her group developed widely used algorithms for modeling transcriptional and epigenetic gene regulation (MACS, Cistrome, MDscan, BETA), analyzing CRISPR screens (MAGeCK), and characterizing tumor immunity (TIMER, TIDE, TRUST). She also contributed to the discovery of cancer drug response biomarkers, drug resistance mechanisms, and effective combination therapies. She has published over 250 peerreviewed papers, and has an H-index of 106.

Dr. Liu is a fellow of the International Society of Computational Biology (ISCB), American Institute for Medical and Biological Engineering (AIMBE), and was a Breast Cancer Research Foundation Investigator (2017-2021). She is a recipient of the Sloan Research Fellowship (2008), Weitzman Outstanding Early Career Investigator Award from the Endocrine Society (2016), ISCB Innovator Award (2020), and the Benjamin Franklin Award for Open Access in the Life Sciences (2020). Her lab has mentored 25 trainees to independent faculty positions.

Alan Xu, Ph.D.

CEO @ MediLink Tx (USA)

Dr. Alan Xu currently is the CEO of MediLink Therapeutics, USA and SVP of Suzhou MediLink Therapeutics. Dr. Xu is responsible for the clinical development of MediLink’s clinical assets, in both China and US. Before joining MediLink, Dr. Xu worked with various MNCs and biotechs in China and US. Dr. Xu holds a Ph.D. from the University of Florida.

Lily Zou, Ph.D.

Co-founder & CEO @ Degron Therapeutics

Lily Zou is co-founder and CEO of Degron Therapeutics, a biotech company focused on the discovery and development of innovative molecular glue degrader drugs for novel disease targets utilizing it proprietary technology platform. Prior to Degron, Lily was CEO of Fosun Pharma USA and VP of Fosun Pharma Group, where she built and grew Fosun Pharma’s US business with R&D, commercial and investment capabilities, and served as chairman or member of the board of four Fosun portfolio companies, Archimmune Therapeutics, Nature’s Sunshine Products (NASDAQ: NATR), NovelStar and Glycotest. Lily worked at top management consulting firm (Bain & Co.), large pharmas (Novartis, Wyeth, Fosun), and smaller biotechs (ArQule, Coley Pharmaceutical Group) in various functions including BD&L, R&D management, drug discovery, and commercialization.

Lily holds a Ph.D. in Microbiology and Immunology from Cornell University, an MBA from MIT, and a B.S. in Biology from Beijing University.

活动协办组织

About us

BioSpark

BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。

BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.

成为BioSpark会员：BioSpark期待您的加入--会员推荐与申请

Follow us on Twitter:
https://twitter.com/BioSpark_Group

Follow us on LinkedIn:
https://www.linkedin.com/company/biospark-group

BioSpark events Calendar:
https://tinyurl.com/tcwy44t6

Email us: [email protected]